Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Matzke is active.

Publication


Featured researches published by Michael Matzke.


Bioorganic & Medicinal Chemistry Letters | 2003

Novel antifungal β-amino acids: Synthesis and activity against Candida albicans

Joachim Mittendorf; Franz Kunisch; Michael Matzke; Hans-Christian Militzer; Axel Schmidt; Wolfgang Schonfeld

A series of novel beta-amino acids has been synthesized and tested for their in vitro antifungal activity against Candida albicans. A steep SAR was observed. beta-Amino acid 21 (BAY 10-8888/PLD-118) revealed the most favourable activity-tolerability profile and was selected for clinical studies as a novel antifungal for the oral treatment of yeast infections.


Inflammation Research | 1994

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.

Armin Hatzelmann; R. Fruchtmann; K. H. Mohrs; Siegfried Raddatz; Michael Matzke; U. Pleiss; J. Keldenich; Reiner Muller-Peddinghaus

Five-lipoxygenase (5-LOX) inhibition is gaining increasing importance as a novel approach to therapy of allergic asthma and other inflammatory diseases. Presently, two types of inhibitors are known, direct 5-LOX inhibitors (LOI) and the FLAP (five lipoxygenase activating protein) binding leukotriene synthesis inhibitors (LSI). The 5-LOX selective and orally active quinoline LSI, BAY X 1005, shares many mechanistic features with the indole LSI, MK-886. The binding of BAY X 1005 to FLAP correlates with LTB4 synthesis inhibition. BAY X 1005 has been shown to bind to the 18 kD protein FLAP. BAY X 1005 inhibits 5-LOX translocation from the cytosol to membranes and reverses 5-LOX translocation. The use of BAY X 1005 has helped to elucidate part of the complex FLAP/5-LOX interaction by showing that FLAP appears to represent a 5-LOX substrate transfer protein channelling endogenous and exogenous arachidonic acid to the leukotriene synthetizing 5-LOX. This notion presented by our group in 1992 has stimulated further mechanistic studies. These findings have additionally led to the hypothesis that substrate competition is not confined to the LSI/FLAP interaction but may also be true for the LOI/5-LOX interaction and that even mixed LSI/LOI 5-LOX inhibitors are feasible, yet have not been described. Further mechanistic work on LSI will be orientated not only to further elucidate the complex FLAP/5-LOX interaction, but also to identify FLAP-related eicosanoid binding proteins.


Archive | 1998

Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Klaus-Helmut Mohrs; Siegfried Raddatz; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schuhmacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl; Frank Mauler; Jean De Vry; Reinhard Jork


Archive | 2001

Use of known agonists of the central cannabinoid receptor CB1

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schuhmacher; Arno Friedl; Ervin Horvath; Frank Mauler; Jean-Marie-Viktor De Vry; Reinhard Jork


Archive | 1992

Heterocyclic substituted phenylacetic-acid derivatives, process for their preparation and their pharmaceutical application

Ulrich Dr. Müller; Klaus Mohrs; Jürgen Dr. Dressel; Rudolf Dr. Hanko; Walter Dr. Hübsch; Michael Matzke; Ulrich Niewohner; Siegfried Raddatz; Thomas Dr. Krämer; Matthias Dr. Müller-Gliemann; Hans-Peter Dr. Bellemann; Martin Dr. Beuck; Stanislav Kazda; Stefan Wohlfeil


Archive | 1997

Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases

Michael Matzke; Uwe Petersen; Thomas Jaetsch; Stephan Bartel; Thomas Schenke; Thomas Himmler; Bernd Baasner; Hans-Otto Werling; Klaus Schaller; Harald Labischinski


Archive | 1992

2-Substituted quinolines, process for their preparation as well as their use in medicaments

Siegfried Raddatz; Klaus-Helmut Mohrs; Michael Matzke; Romanis Fruchtmann; Armin Hatzelmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus; Pia Theisen-Popp


Archive | 1993

Cyclopentane- and -pentene-β-amino acids

Joachim Mittendorf; Franz Kunisch; Michael Matzke; Hans-Christian Militzer; Rainer Endermann; Karl Georg Metzger; Klaus-Dieter Bremm; Manfred Plempel


Archive | 1999

Aryl sulphonamides and analogues

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Frank Mauler; Jean-Marie-Victor de Vry; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schumacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl; Klaus-Helmut Mohrs; Siegfried Raddatz; Reinhard Jork


Archive | 1999

Aryl sulphonamide amino acid esters and analogues

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Frank Mauler; Jean-Marie-Viktor De Vry; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schumacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl

Researchain Logo
Decentralizing Knowledge